Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 13/20 | 1.00 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7650022 | 0.85 | TNF (0.73) | TNFCTNNB1ALDH1A1 | |
| SCHEMBL7654430 | 0.82 | TNF (0.70) | TNFCTNNB1HDAC1ALDH1A1KDM4E | |
| SCHEMBL7649768 | 0.82 | TNF (0.70) | TNFCTNNB1HDAC1ALDH1A1KDM4E | |
| SCHEMBL7650027 | 0.81 | TNF (0.68) | TNFCTNNB1ALDH1A1KDM4E | |
| SCHEMBL7656518 | 0.80 | TNF (0.67) | TNFCTNNB1ALDH1A1KDM4E | |
| SCHEMBL14560541 | 0.80 | PGR (0.67) | TNFHDAC1ALDH1A1KDM4E | |
| SCHEMBL12938925 | 0.79 | TNF (0.64) | TNFCTNNB1HDAC1ALDH1A1KDM4E | |
| SCHEMBL1004476 | 0.78 | TNF (0.63) | TNFCTNNB1HDAC1ALDH1A1KDM4E | |
| SCHEMBL1004093 | 0.78 | TNF (0.63) | TNFCTNNB1HDAC1ALDH1A1KDM4E | |
| SCHEMBL5036947 | 0.77 | TNF (0.62) | TNFHDAC1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6562819-B2 | Antiinflammatory agents; antiproliferative agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-05-13 | — | — | US | disclosed |
| US-20020165202-A1 | Compounds for inhibition of ceramide-mediated signal transduction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-11-07 | — | — | US | disclosed |
| EP-1193257-A2 | Compounds for ceramide-mediated signal transduction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6323201-B1 | ANTIINFLAMMATORY AGENTS, ANTIPROLIFERATION AGENTS AND ENZYME INHIBITORS OF PHOSPHODIESTERASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-11-27 | — | — | US | disclosed |
| US-5843943-A | Compounds for inhibition of ceramide-mediated signal transduction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-12-01 | — | — | US | disclosed |
| WO-1996020710-A1 | COMPOUNDS FOR INHIBITION OF CERAMIDE-MEDIATED SIGNAL TRANSDUCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165202-A1 | Compounds for inhibition of ceramide-mediated signal transduction | SMPD1, CERT1, SMPD3 | TNF 13/4885CTNNB1 2436/4885HDAC1 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.